Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Preoperative and Postoperative Imatinib in GIST
NCT00500188Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jul 2003
- Primary completion
- Jul 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of imatinib in gastrointestinal stromal tumor (GIST) (3 arms), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoints: Disease-Free Survival at 2 years, Induction of Apoptosis and 1 more. Started Jul 2003; status: completed.
02
Drugs
03
Conditions
gastrointestinal stromal tumor (GIST)
Beyond the preview
Go deeper on NCT00500188.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00500188.